Goal Guide · 2026

Best Peptides for Muscle Growth

Summary

For muscle growth, the strongest evidence points to Lenomorelin, Liraglutide, and Dulaglutide. Lenomorelin directly stimulates growth hormone secretion, a key driver of muscle protein synthesis and body composition. Liraglutide and Dulaglutide support an anabolic environment by reducing adiposity and improving insulin sensitivity, which indirectly favors lean mass retention. All three carry Grade A evidence ratings based on clinical trial data.

Understanding Muscle Growth with Peptides

Muscle growth depends on anabolic signaling pathways, primarily driven by growth hormone, IGF-1, and insulin. Peptides can intervene at several points in this cascade. Ghrelin mimetics like Lenomorelin stimulate pituitary release of growth hormone, which subsequently elevates IGF-1 levels in peripheral tissues. Elevated IGF-1 activates mTOR signaling in skeletal muscle, promoting protein synthesis and satellite cell proliferation. GLP-1 receptor agonists contribute through a different mechanism: by improving insulin sensitivity and reducing systemic inflammation, they create a metabolic environment more permissive to lean mass accrual.

Two peptide classes are most relevant to muscle growth outcomes. The first is growth hormone secretagogues, represented here by Lenomorelin, which directly amplify endogenous GH pulsatility without exogenous hormone administration. The second class is GLP-1 receptor agonists, including Liraglutide, Dulaglutide, Exenatide, Albiglutide, and Lixisenatide. While primarily studied for glycemic control and weight loss, GLP-1 agonists reduce visceral adiposity and hyperinsulinemia, both of which are documented antagonists of skeletal muscle hypertrophy. Reduced fat mass with preserved lean mass is a consistently reported outcome in longer-duration GLP-1 trials.

The evidence base for peptides and muscle growth is stratified. Lenomorelin holds Grade A evidence specifically for GH secretion and appetite stimulation, with secondary data supporting improvements in lean body mass in GH-deficient and aging populations. GLP-1 agonists such as Liraglutide and Dulaglutide have robust Grade A evidence from large cardiovascular outcomes trials, where body composition changes were secondary endpoints. Direct hypertrophy endpoints are less commonly reported in GLP-1 literature, but the mechanistic and indirect data supporting lean mass preservation are well-documented. Researchers evaluating this category should distinguish between direct anabolic effects and supportive metabolic remodeling.

Peptides Ranked by Evidence (54 found)

Peptide	Evidence	Primary Mechanism
Albiglutide	AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved	Promotes weight loss via appetite suppression	Research →
Dulaglutide	AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved	Significant weight loss (2-4 kg average)	Research →
Exenatide	AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved	Promotes weight loss	Research →
Lenomorelin	AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved	Stimulates growth hormone secretion	Research →
Liraglutide	AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved	Promotes significant weight loss	Research →
Lixisenatide	AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved	Promotes modest weight loss	Research →
Macimorelin	AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved	Diagnostic assessment of growth hormone secretory capacity	Research →
Retatrutide	AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved	Exceptional weight loss (up to 24% body weight)	Research →
Semaglutide	AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved	Significant weight loss (average 15-20% body weight)	Research →
Tesamorelin	AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved	Supports GH production	Research →
Tirzepatide	AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved	Superior weight loss compared to semaglutide (average 20-25%)	Research →
ACE-031	BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries	Increases skeletal muscle mass and strength	Research →
AOD-9604	BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries	Supports weight loss	Research →
Anamorelin	BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries	Enhances body weight in wasting conditions	Research →
CJC-1295	BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries	Increases growth hormone and IGF-1 levels	Research →
Sermorelin	BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries	Increases natural GH production	Research →
Tesofensine	BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries	Promotes weight loss in obesity	Research →
Alexamorelin	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	Stimulates growth hormone secretion	Research →
Argireline	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	Decreases facial muscle contraction intensity	Research →
BPC-157	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	Repairs tendons, ligaments, and muscle tissue	Research →
CJC-1293	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	Stimulates growth hormone secretion	Research →
Cardiogen	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	Supports cardiac muscle function and contractility	Research →
Follistatin	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	Dramatic increase in muscle mass	Research →
GHRP-1	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	Stimulates growth hormone release	Research →
GHRP-2	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	Potent GH secretagogue	Research →
GHRP-3	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	Stimulates growth hormone secretion	Research →
GHRP-4	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	Stimulates growth hormone secretion	Research →
GHRP-5	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	Stimulates growth hormone release	Research →
GHRP-6	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	Increases GH and IGF-1 levels	Research →
Hexarelin	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	Very potent GH release	Research →
IGF-1 DES	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	Promotes localized muscle hypertrophy	Research →
IGF-1 LR3	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	Promotes significant muscle growth	Research →
Ipamorelin	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	Stimulates growth hormone release	Research →
Livagen	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	May improve liver-derived protein synthesis	Research →
MGF	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	Promotes localized muscle repair and growth	Research →
PEG-MGF	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	Promotes muscle fiber repair	Research →
Snap-8	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	Inhibits facial muscle contractions	Research →
TB-500	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	Reduces inflammation throughout the body	Research →
Tabimorelin	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	Stimulates growth hormone secretion	Research →
Vesilute	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data	May enhance bladder smooth muscle tone	Research →
5-Amino-1MQ	DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence	Promotes fat loss and weight reduction	Research →
Decapeptide-12	DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence	Evens skin tone and brightens complexion	Research →
Desmopressin		Reduces nocturnal polyuria and nighttime urination	Research →
Enkephalins (Met-Enkephalin, Leu-Enkephalin)		Modulates pain perception through opioid receptors	Research →
Leuphasyl	DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence	Reduces muscle contraction	Research →
Melanostatin DM	DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence	Brightens skin tone and evens complexion	Research →
Metformin		Supports weight management and fat loss	Research →
Myostatin	DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence	Increases skeletal muscle mass and strength	Research →
Nonapeptide-1	DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence	Lightens hyperpigmentation and age spots	Research →
Pentadecapeptide BPC 157		Heals muscle tears	Research →
Pramlintide		May support modest weight loss	Research →
Syn-Ake	DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence	Relaxes facial muscles	Research →
Vialox	DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence	Relaxes facial muscles non-invasively	Research →
YK11	DEvidenceGrade DTheoretical or in-vitro only; no meaningful independent human evidence	Increases muscle mass and strength	Research →

Top Picks by Evidence Grade

Albiglutide

AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved

Promotes weight loss via appetite suppression

View research page →

Dulaglutide

AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved

Significant weight loss (2-4 kg average)

View research page →

Exenatide

AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved

Promotes weight loss

View research page →

Lenomorelin

AEvidenceGrade ALarge human randomised controlled trials or FDA/major-authority approved

Stimulates growth hormone secretion

View research page →

Getting Started

Identify Your Physiological Target

Determine whether the primary goal is direct GH-mediated hypertrophy or metabolic optimization to support lean mass. Research suggests these two pathways require different peptide classes, and selecting the wrong category may yield suboptimal outcomes for the specific mechanism being studied.

Review Available Clinical Evidence

Prioritize peptides with Grade A evidence such as Lenomorelin for GH secretion or Liraglutide for metabolic body composition changes. Cross-referencing peer-reviewed trial data helps establish realistic expectations for the magnitude and timeline of lean mass effects observed in research populations.

Assess Complementary Outcome Markers

Clinical research protocols for muscle growth typically track markers such as IGF-1 levels, lean body mass via DEXA, fasting insulin, and HbA1c alongside primary endpoints. Selecting a peptide with multi-marker relevance, such as Lenomorelin for GH and appetite or Dulaglutide for insulin sensitivity and weight, can provide a more comprehensive picture of anabolic status.

Related Side-by-Side Comparisons

Detailed evidence comparisons for the top muscle growth peptides.

cjc 1295 vs ipamorelin

Compare →

sermorelin vs ipamorelin

Compare →

Frequently Asked Questions

Do peptides for muscle growth work differently than anabolic steroids?⌄

Yes, the mechanisms are distinct. Peptides like Lenomorelin stimulate the pituitary to release endogenous growth hormone rather than introducing exogenous androgens. GLP-1 agonists improve metabolic conditions rather than directly activating androgen receptors. Research indicates this results in different side effect profiles and a more indirect anabolic stimulus compared to steroidal compounds.

Can GLP-1 agonists genuinely support muscle growth, or do they only cause weight loss?⌄

GLP-1 receptor agonists primarily reduce fat mass, but multiple clinical trials report preservation of lean body mass during weight loss phases when protein intake and resistance activity are maintained. Improved insulin sensitivity, a documented effect of Liraglutide and Dulaglutide, reduces insulin resistance in muscle tissue, which supports glucose uptake and glycogen storage relevant to muscle performance and recovery.

How long does research suggest it takes for peptides to show measurable effects on muscle composition?⌄

Study durations vary by peptide class. GH secretagogue research like Lenomorelin often reports measurable IGF-1 changes within weeks, but lean mass changes in clinical trials typically require 12 to 26 weeks of observation. GLP-1 agonist trials reporting body composition endpoints commonly span 52 weeks or longer, reflecting the slower pace of metabolic remodeling versus direct anabolic stimulation.

Are there peptides that combine appetite stimulation with anabolic signaling for muscle growth research?⌄

Lenomorelin is notable in this context because it simultaneously stimulates growth hormone secretion and increases appetite and food intake, both of which are relevant to supporting a caloric surplus necessary for muscle hypertrophy. This dual mechanism makes it a distinct research candidate compared to GLP-1 agonists, which suppress appetite and are better suited to lean mass preservation during caloric restriction rather than mass accumulation phases.

Not sure where to start?

The Goal Finder asks 3 questions and gives you a personalised peptide recommendation ranked by evidence grade.

Use Goal Finder →Compare Peptides

Explore Other Goals

Fat Loss Better Sleep Recovery and Healing Cognitive Performance Longevity and Anti-Aging Sexual Health Anxiety and Mood Skin Health Immune Support